Amiloride
Classification: BATC code: C03DB01, C03EA01
Summary
Controlled studies on differences between men and women on effect, safety and pharmacokinetics for amiloride are lacking.
Additional information
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of amiloride have been found.
Dosing
No studies with a clinically relevant sex analysis regarding the dosing of amiloride have been found.
Effects
No conclusive studies with a clinically relevant sex analysis regarding the effects of amiloride have been found.
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of amiloride have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Other information
A large British randomized, placebo-controlled, single-blind trial compared treatment with hydrochlorothiazide plus amiloride and atenolol in hypertensive older adults (in total 1836 men, 2560 women). Number of deaths from cancer among patients taking diuretic was higher in men than women (0.7% of men 0.3% of women on diuretics compared to 0.5% of men and 0.6% of women with placebo) [1]. These results have unclear relevance today. The cancer mortality rates in UK have fallen by 19% for women and 29% for men between 1990-2016 [2].
Updated: 2019-04-08
Date of litterature search: 2019-03-11
References
- MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results . British Medical Journal. 1992;304:405-412.
- Cancer Research UK. Cancer Stats: Cancer Statistics for the UK. Cancer Research UK [www]. [cited 2019-03-28]. länk
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.] länk
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson